Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 143

1.

Design and synthesis of new tripeptide-type SARS-CoV 3CL protease inhibitors containing an electrophilic arylketone moiety.

Konno S, Thanigaimalai P, Yamamoto T, Nakada K, Kakiuchi R, Takayama K, Yamazaki Y, Yakushiji F, Akaji K, Kiso Y, Kawasaki Y, Chen SE, Freire E, Hayashi Y.

Bioorg Med Chem. 2013 Jan 15;21(2):412-24. doi: 10.1016/j.bmc.2012.11.017. Epub 2012 Nov 24.

PMID:
23245752
2.

Design, synthesis, and biological evaluation of novel dipeptide-type SARS-CoV 3CL protease inhibitors: structure-activity relationship study.

Thanigaimalai P, Konno S, Yamamoto T, Koiwai Y, Taguchi A, Takayama K, Yakushiji F, Akaji K, Kiso Y, Kawasaki Y, Chen SE, Naser-Tavakolian A, Schön A, Freire E, Hayashi Y.

Eur J Med Chem. 2013 Jul;65:436-47. doi: 10.1016/j.ejmech.2013.05.005. Epub 2013 May 20.

PMID:
23747811
3.

Development of potent dipeptide-type SARS-CoV 3CL protease inhibitors with novel P3 scaffolds: design, synthesis, biological evaluation, and docking studies.

Thanigaimalai P, Konno S, Yamamoto T, Koiwai Y, Taguchi A, Takayama K, Yakushiji F, Akaji K, Chen SE, Naser-Tavakolian A, Schön A, Freire E, Hayashi Y.

Eur J Med Chem. 2013 Oct;68:372-84. doi: 10.1016/j.ejmech.2013.07.037. Epub 2013 Aug 9.

PMID:
23994330
4.

Discovery of a novel family of SARS-CoV protease inhibitors by virtual screening and 3D-QSAR studies.

Tsai KC, Chen SY, Liang PH, Lu IL, Mahindroo N, Hsieh HP, Chao YS, Liu L, Liu D, Lien W, Lin TH, Wu SY.

J Med Chem. 2006 Jun 15;49(12):3485-95.

PMID:
16759091
5.

New developments for the design, synthesis and biological evaluation of potent SARS-CoV 3CL(pro) inhibitors.

Regnier T, Sarma D, Hidaka K, Bacha U, Freire E, Hayashi Y, Kiso Y.

Bioorg Med Chem Lett. 2009 May 15;19(10):2722-7. doi: 10.1016/j.bmcl.2009.03.118. Epub 2009 Mar 28.

6.

Design, synthesis, and evaluation of trifluoromethyl ketones as inhibitors of SARS-CoV 3CL protease.

Shao YM, Yang WB, Kuo TH, Tsai KC, Lin CH, Yang AS, Liang PH, Wong CH.

Bioorg Med Chem. 2008 Apr 15;16(8):4652-60. doi: 10.1016/j.bmc.2008.02.040. Epub 2008 Feb 15.

PMID:
18329272
7.

Structure-based drug design and structural biology study of novel nonpeptide inhibitors of severe acute respiratory syndrome coronavirus main protease.

Lu IL, Mahindroo N, Liang PH, Peng YH, Kuo CJ, Tsai KC, Hsieh HP, Chao YS, Wu SY.

J Med Chem. 2006 Aug 24;49(17):5154-61.

PMID:
16913704
8.

Biflavonoids from Torreya nucifera displaying SARS-CoV 3CL(pro) inhibition.

Ryu YB, Jeong HJ, Kim JH, Kim YM, Park JY, Kim D, Nguyen TT, Park SJ, Chang JS, Park KH, Rho MC, Lee WS.

Bioorg Med Chem. 2010 Nov 15;18(22):7940-7. doi: 10.1016/j.bmc.2010.09.035. Epub 2010 Sep 19.

PMID:
20934345
9.

Screening of drugs by FRET analysis identifies inhibitors of SARS-CoV 3CL protease.

Liu YC, Huang V, Chao TC, Hsiao CD, Lin A, Chang MF, Chow LP.

Biochem Biophys Res Commun. 2005 Jul 22;333(1):194-9.

PMID:
15950190
10.
11.

Binding interaction of quercetin-3-beta-galactoside and its synthetic derivatives with SARS-CoV 3CL(pro): structure-activity relationship studies reveal salient pharmacophore features.

Chen L, Li J, Luo C, Liu H, Xu W, Chen G, Liew OW, Zhu W, Puah CM, Shen X, Jiang H.

Bioorg Med Chem. 2006 Dec 15;14(24):8295-306. Epub 2006 Oct 12.

PMID:
17046271
12.

Synthesis, docking studies, and evaluation of pyrimidines as inhibitors of SARS-CoV 3CL protease.

Ramajayam R, Tan KP, Liu HG, Liang PH.

Bioorg Med Chem Lett. 2010 Jun 15;20(12):3569-72. doi: 10.1016/j.bmcl.2010.04.118. Epub 2010 May 20.

PMID:
20494577
13.

Peptide aldehyde inhibitors challenge the substrate specificity of the SARS-coronavirus main protease.

Zhu L, George S, Schmidt MF, Al-Gharabli SI, Rademann J, Hilgenfeld R.

Antiviral Res. 2011 Nov;92(2):204-12. doi: 10.1016/j.antiviral.2011.08.001. Epub 2011 Aug 11.

PMID:
21854807
15.

Structure-based design and synthesis of highly potent SARS-CoV 3CL protease inhibitors.

Shao YM, Yang WB, Peng HP, Hsu MF, Tsai KC, Kuo TH, Wang AH, Liang PH, Lin CH, Yang AS, Wong CH.

Chembiochem. 2007 Sep 24;8(14):1654-7. No abstract available.

PMID:
17722121
16.

Development of broad-spectrum halomethyl ketone inhibitors against coronavirus main protease 3CL(pro).

Bacha U, Barrila J, Gabelli SB, Kiso Y, Mario Amzel L, Freire E.

Chem Biol Drug Des. 2008 Jul;72(1):34-49. doi: 10.1111/j.1747-0285.2008.00679.x.

17.

Synthesis, modification and docking studies of 5-sulfonyl isatin derivatives as SARS-CoV 3C-like protease inhibitors.

Liu W, Zhu HM, Niu GJ, Shi EZ, Chen J, Sun B, Chen WQ, Zhou HG, Yang C.

Bioorg Med Chem. 2014 Jan 1;22(1):292-302. doi: 10.1016/j.bmc.2013.11.028. Epub 2013 Nov 21.

PMID:
24316352
18.

Flavonoid-mediated inhibition of SARS coronavirus 3C-like protease expressed in Pichia pastoris.

Nguyen TT, Woo HJ, Kang HK, Nguyen VD, Kim YM, Kim DW, Ahn SA, Xia Y, Kim D.

Biotechnol Lett. 2012 May;34(5):831-8. doi: 10.1007/s10529-011-0845-8. Epub 2012 Feb 15.

PMID:
22350287
19.

Development of anti-coxsackievirus agents targeting 3C protease.

Kim BK, Kim JH, Kim NR, Lee WG, Lee SD, Yun SH, Jeon ES, Kim YC.

Bioorg Med Chem Lett. 2012 Nov 15;22(22):6952-6. doi: 10.1016/j.bmcl.2012.08.120. Epub 2012 Sep 8.

PMID:
23062551
20.
Items per page

Supplemental Content

Write to the Help Desk